Therapeutically Applicable Research to Generate Effective Treatments (TARGET)

产生有效治疗方法的治疗应用研究（目标）

• 批准号: 8654778
• 负责人: DAVID HEIMBROOK
• 金额: $ 35万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-26 至 2018-09-25
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8654778
• 关键词: Adult; Adverse effects; Cancer Therapy Evaluation Program; Child; Children' s Oncology Group; Chromosomes; Collaborations; DNA Resequencing; DNA Sequence; Data; Development; Gene Expression; Gene Expression Profile; Genes; Genetic; Genome; Genomics; Goals; Health; Malignant Childhood Neoplasm; Malignant Neoplasms; Methods; Molecular Target; Mutation; Office of Cancer Genomics; Outcome; RNA Interference; Reading; Research; Resolution; Sampling; Services; Structure; System; Techniques; The Cancer Genome Atlas; Translations; Ursidae Family; base; cancer genomics; cancer therapy; clinical application; effective therapy; novel; programs; structural genomics; therapeutic target

The goal of NCI's Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative is to identify valid therapeutic targets in childhood cancers so that new, more effective treatments can be rapidly developed. TARGET is coordinated by the Office of Cancer Genomics (OCG) and the Cancer Therapy Evaluation Program (CTEP). There is an overwhelming need for new treatment approaches to childhood cancers. The early victories in health outcomes of the last several decades for children with cancer have slowed. Furthermore, the current treatments for childhood cancers can have serious short- and long-term side effects, and recent molecularly targeted therapy advances have been largely limited to the treatment of adult cancers. The TARGET Initiative seeks to help bring the new era of targeted cancer therapy to bear on the cancers that afflict children. In pursuing its goals, TARGET leverages the strengths of other NCI programs, including the Children's Oncology Group (COG), The Cancer Genome Atlas (TCGA), and the Strategic Partnership to Evaluate Cancer Signatures (SPECS). These collaborations should expedite the discovery of therapeutic targets and catalyze the translation of these findings for clinical application with the ultimate goal of reducing the burden of childhood cancer. SAIC obtains nextgen sequencing capabilities and procures data coordination services.

NCI的治疗性研究的目的是生成有效的治疗（目标）倡议是确定儿童期癌症中有效的治疗靶标，以便可以快速开发新的，更有效的治疗方法。癌症基因组学办公室（OCG）和癌症治疗评估计划（CTEP）协调了目标。 对儿童癌症的新治疗方法有压倒性的需求。过去几十年来，癌症儿童的健康成果的早期胜利减慢了。此外，目前的儿童癌症治疗方法可能会产生严重的短期和长期副作用，而最近的分子靶向疗法进步很大程度上仅限于对成年癌症的治疗。目标倡议旨在帮助将有针对性的癌症治疗的新时代忍受困扰儿童的癌症。 在追求目标时，目标利用其他NCI计划的优势，包括儿童肿瘤学组（COG），癌症基因组地图集（​​TCGA）和战略合作伙伴关系来评估癌症特征（SPECS）。这些合作应加快发现治疗靶点的发现，并催化这些发现的临床应用，以减轻儿童癌症负担的最终目标。 SAIC获得了NextGen测序功能，并获得数据协调服务。